Canada markets close in 1 hour 47 minutes

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9400+0.0400 (+2.06%)
As of 02:10PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.9000
Open1.9800
Bid2.1400 x 900
Ask1.9900 x 200
Day's Range1.9400 - 1.9980
52 Week Range1.8200 - 11.8200
Volume10,117
Avg. Volume39,928
Market Cap4.214M
Beta (5Y Monthly)2.92
PE Ratio (TTM)N/A
EPS (TTM)-14.2900
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.25
  • GlobeNewswire

    GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

    ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024. Presentation Details:Present

  • GlobeNewswire

    GeoVax to Present at the 36th Annual Roth Conference

    ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024. Presentation Details: Presenter: David Dodd, Chairman & CEODate/Time: March 18, 2024, 2:30 pm PTLocation: Dana Point, CAWebcast Link: Ro

  • GlobeNewswire

    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

    Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a significant milestone toward implementation of a validated chicken embryonic fibroblast (CEF) based production system for the company’s MVA-based vaccines, with the relea